Scientists have developed a new method for determining ebastine in its pharmaceutical preparations, according to 7th Space Interactive.
The news source reported that this model depends on the complexation ability of the studied drug with Zn2+ ions. Reversed phase chromatography
was carried out using an ODS c18 stainless steel column with UV-detection at 260nm.
Furthermore, a mobile phase containing 0.025 per cent w/v Zn2+ in a mixture of (acetonitril/methanol) and Britton Robinson buffer, which was adjusted to a pH of 4.2, was used to determine the ebastine at a flow rate of one ml/min.
It was also reported that content uniformity testing of the method was also conducted, while the make-up of the complex and its stability constant was looked into.
Recently, liquid chromatography
was used to analyse endometrial hyperplasia and carcinoma, with findings published in the Journal of Hematology and Oncology, highlighting that these gynaecological malignancies are the most common.